Jul 19th 2012 - Edison Investment Research today published a report on quickview entitled "Overcoming Resistance". In summary, the report says:
NovaBay’s 10-year development of novel anti-infective agents is entering a potentially transformational 12-month period, which could break through stubborn resistance in its stock since IPO in 2007. Phase IIb trial read outs for lead compound NVC-422 in three significant unmet needs and potential development/commercial partnerships offer multiple catalysts. We believe the potential in NovaBay’s Aganocide compounds, with demonstrated ability to overcome and avoid resistance issues that plagues the anti-infective market, is at odds with an EV of $24.2m.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »